Basecamp Research has raised $140m in an oversubscribed Series C round to expand its biological artificial-intelligence models and advance a pipeline of AI-designed medicines towards clinical development.
The London-headquartered company said the round was led by S32, with investors including Nvidia, Anthropic’s Anthology Fund, NATO Innovation Fund, The Rockefeller Foundation, Catalio Capital Management, Redalpine, Singular, True Ventures, and other technology and life-sciences backers.
Reuters reported that the financing values Basecamp at approximately $800m. The company has focused its announcement on plans to use the capital to train a new generation of its EDEN biological models and develop therapeutic programmes.
Co-founder and chief executive Glen Gowers said: “We believe the future of medicine lies in reprogramming the body to repair itself.”
Basecamp combines machine-learning models with biological data and DNA-design technology. Its EDEN models are trained using the company’s Trillion Gene Atlas, a proprietary biological dataset assembled through partnerships spanning more than 30 countries.
The first area of therapeutic development is in vivo cell therapy, which seeks to alter cells inside the patient rather than relying entirely on cells being removed, modified externally, and returned. Basecamp argues that its models can design long and complex DNA sequences that could support more sophisticated and potentially easier-to-administer treatments.
The company says it has produced preclinical results across multiple therapeutic modalities and disease areas. It is also expanding pharmaceutical partnerships and has appointed former Biogen executive Richard Pearce as chief business officer.
The financing brings together two capital-intensive industries. Frontier AI requires substantial computing infrastructure, specialist data, and scarce technical talent, while drug development requires laboratory work, regulatory engagement, clinical trials, and long development timelines before a treatment can reach patients.
That makes AI-led biotechnology a demanding test of the current investment cycle. Software businesses can often deploy products quickly and gather commercial feedback immediately. Therapeutic developers have to show that computational predictions translate into biological effects and, later, that those effects are safe and clinically useful.
Basecamp’s strategy seeks an advantage through proprietary training data. General-purpose models can draw from large quantities of published information, but drug developers increasingly compete around specialised datasets that competitors cannot easily reproduce. The Trillion Gene Atlas is intended to expose EDEN to biological diversity that is underrepresented in conventional datasets.
The approach also places governance around data collection alongside scientific performance. Basecamp says the Atlas is built through access and benefit-sharing partnerships, giving the business a framework for collecting biological information across different geographies while working with local partners.
Investment from major technology and institutional backers indicates continued appetite for businesses applying advanced AI beyond general-purpose software. It also adds to the private capital flowing into infrastructure, models, scientific platforms, and applications surrounding the broader AI investment cycle.
The harder milestones still lie ahead. Basecamp now has to move therapeutic candidates towards clinical development, expand pharmaceutical partnerships, and demonstrate that programmes designed through its models can produce repeatable results in medicine.
The $140m round provides substantially more capital for that transition. Whether the technology creates durable value will ultimately depend on clinical outcomes rather than the sophistication of the models alone.
You must be logged in to post a comment.